Joseph A. Garcia
Joseph A. Garcia
(604) 631-3307
(604) 631-3309
595 Burrard St, Suite 2600, PO Box 49314, 3 Bentall Ctr, Vancouver, BC
Year called to bar: 1997 (BC)
Joseph is a partner who practises in the areas of corporate finance and mergers & acquisitions. He advises public and private companies, investment dealers, venture capital, and private equity funds, and acts as independent counsel to boards of directors. Joseph has extensive experience advising on all types of domestic and cross-border, merger & acquisition, and corporate finance transactions, including public and private equity and debt financings, takeover and issuer bids, share and asset acquisitions and divestitures, and regulatory and stock exchange compliance work. Prior to his career in law, Joseph worked in corporate finance with a national investment bank and in clinical research with a multinational pharmaceutical company. Joseph is a director of Genome BC and Chair of its Audit Committee. He is also Director Emeritus of Life Sciences BC. In addition, he is a director of the Canadian Glycomics Network and a member of the BIOTE Canada Legal Affairs Advisory Board, the Canadian Bar Association, and the American Bar Association. He is recognized as a leading lawyer in all major legal directories and ranking publications.
Joseph A. Garcia is a featured Leading Lawyer in:
Canadian Legal Lexpert Directory
Consistently Recommended
Canadian Legal Lexpert Directory
Consistently Recommended
Canadian Legal Lexpert Directory
Repeatedly Recommended
Canadian Legal Lexpert Directory
Consistently Recommended
Canadian Legal Lexpert Directory
Repeatedly Recommended
Canadian Legal Lexpert Directory
Repeatedly Recommended
Read more about Joseph A. Garcia in ...
British Columbia’s top corporate mid-market lawyers in 2021
Lexpert unveils British Columbia's top corporate mid-market lawyers
Canada’s leading biotechnology lawyers
Lexpert presents the Canada’s leading biotechnology lawyers based on the results of our comprehensive yearly peer survey
On June 11, 2018, Zymeworks Inc. (Zymeworks) closed its underwritten public offering of 6,210,000 common shares, including the underwriters’ full exercise of their over-allotment option to purchase 810,000 additional shares, at a price to the public of US$15.75 per common share, for aggregate gross proceeds to the Company of approximately US$97.8 million, before deducting the underwriting discounts and commissions and estimated Offering expenses.
On August 14, 2018, Aurora Cannabis Inc. (TSX: ACB) (OTCQB: ACBFF) (Frankfurt: 21P; WKN: A1C4WM) completed its June-announced acquisition of Anandia Laboratories Inc. in an all-stock transaction valued at $118 million pursuant to a court ordered plan of arrangement.
On May 3, 2017, Zymeworks Inc. completed its initial public offering (the Offering) of 4,500,000 common shares at an initial offering price of US$13.00 per share.
On February 7, 2017, Trilogy International Partners Inc. (formerly Alignvest Acquisition Corporation) (TSX:AQX.A)(TSX:AQX.WT) (“Trilogy”) completed its qualifying acquisition under which Trilogy effected a business combination with Trilogy International Partners LLC by way of a court approved plan of arrangement.
On October 15, 2015, CPI Card Group Inc. (the Company) completed its initial public offering of 17,250,000 shares of common stock at US$10.00 per share, including 2,250,000 shares of common stock sold by certain existing stockholders upon the exercise in full by the underwriters of their over-allotment option.
SciVac Therapeutics Inc., formerly Levon Resources Ltd. and SciVac Ltd. closed a plan of arrangement pursuant to which SciVac completed a reverse takeover of Levon.
On April 7, 2015, Trillium Therapeutics Inc. completed its underwritten public offering of common shares and Series II non-voting convertible first preferred shares in the United States.